Reviewing Assembly Biosciences Inc. (ASMB)’s and MeiraGTx Holdings plc (NASDAQ:MGTX)’s results

Both Assembly Biosciences Inc. (NASDAQ:ASMB) and MeiraGTx Holdings plc (NASDAQ:MGTX) are Biotechnology companies, competing one another. We will compare their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Assembly Biosciences Inc. 14.80M 34.90 90.75M -3.58 0.00
MeiraGTx Holdings plc N/A 0.00 72.78M -2.70 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Assembly Biosciences Inc. and MeiraGTx Holdings plc.

Profitability

Table 2 represents Assembly Biosciences Inc. (NASDAQ:ASMB) and MeiraGTx Holdings plc (NASDAQ:MGTX)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Assembly Biosciences Inc. -613.18% -50.6% -36%
MeiraGTx Holdings plc 0.00% 0% 0%

Liquidity

16.4 and 16.4 are the respective Current Ratio and a Quick Ratio of Assembly Biosciences Inc. Its rival MeiraGTx Holdings plc’s Current and Quick Ratios are 10.8 and 10.8 respectively. Assembly Biosciences Inc. has a better chance of clearing its pay short and long-term debts than MeiraGTx Holdings plc.

Analyst Recommendations

Assembly Biosciences Inc. and MeiraGTx Holdings plc Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Assembly Biosciences Inc. 0 0 2 3.00
MeiraGTx Holdings plc 0 0 0 0.00

The upside potential is 107.61% for Assembly Biosciences Inc. with consensus target price of $42.

Insider and Institutional Ownership

The shares of both Assembly Biosciences Inc. and MeiraGTx Holdings plc are owned by institutional investors at 85.7% and 26.2% respectively. Insiders held roughly 3.3% of Assembly Biosciences Inc.’s shares. Competitively, MeiraGTx Holdings plc has 12.91% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Assembly Biosciences Inc. -5.17% -9.88% -22.32% -48% -64.91% -9.24%
MeiraGTx Holdings plc 22.14% 41.68% 33.28% 54.13% 0% 81.95%

For the past year Assembly Biosciences Inc. has -9.24% weaker performance while MeiraGTx Holdings plc has 81.95% stronger performance.

Summary

On 6 of the 10 factors MeiraGTx Holdings plc beats Assembly Biosciences Inc.

Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its lead product candidate from the platform is AB-M101 that has been completed Phase Ia clinical trial to treat clostridium difficile infections. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.

MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases. It has four ongoing clinical programs, including AAV-RPE65, which is in Phase I/II clinical trials for the treatment of RPE65-deficiency in adult and pediatric patients; AAV-RPGR that is in Phase I/II clinical trials to treat x-linked retinitis pigmentosa in adult and pediatric patients; AAV-CNGB3 that is in Phase I/II clinical trials for the treatment of achromatopsia in adult and pediatric patients; and AAV-AQP1, which is in Phase I/II clinical trials for the treatment of patients with grade 2 or 3 radiation-induced xerostomia. The company also has a pipeline of preclinical and research programs in other indications. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.